Eveline Van Keymeulen, GTNF 2026

Eveline Van Keymeulen is a partner in Latham & Watkins’ Brussels and Paris offices and Global Vice Chair of Latham & Watkins’ Healthcare & Life Sciences Practice.

She advises multinational companies and start-ups in the pharmaceutical, biotech, medical devices, cosmetics, and food and beverage sectors on a broad variety of complex European,
domestic and cross-border regulatory matters, including clinical trials, product approvals, regulatory incentives, market access, promotion and advertising, post-market obligations,
and general compliance matters.
In addition, Eveline has extensive experience advising on cannabis and hemp-based product regulations. She successfully challenged the legality of French hemp regulations in the first
landmark case related to cannabidiol (CBD) products before the Court of Justice of the European Union (Case C-663/18, Kanavape). This transaction won the Creating New
Standards award at the Financial Times European Innovative Lawyer Awards 2022.
Eveline is ranked in Chambers for Life Sciences Regulatory (2020-2025) and has been recognized as a Legal 500 Rising Star / Next Generation Lawyer in Healthcare and Life Sciences (2022-2025), and as a National and Global Leader by Who’s Who Legal Life Sciences (2016-2025). She has recently been awarded the European “Advisory Lawyer of
the Year” and “Impact Case of the Year” awards by LMG Life Sciences (2021-2025).
Eveline has authored numerous articles and has been a featured speaker on EU regulatory matters at prominent conferences such as the Pharmaceutical Law Academy in Cambridge. She also serves on the editorial board of the European Pharmaceutical Law Review.
In addition, Eveline has been quoted in BBC Business Daily, Bloomberg, The Times, Les Echos, and other leading international business journals on life sciences regulatory and
policy matters.

Product category, flavor, birthdates – are bans effective or simply creating new problems. Does legislating a ban get rid of a problem? Bans are being proposed around the world in innovative and traditional forms: phased illegalization based on date of birth, constriction of product attributes and sales channels, and, of course, outright prohibitions. Measures are gaining traction from one geography to another. But if we dive deeper, what is a ban, and what does it actually do? Bans are simple and easy to package to constituents: "Because of X, we are banning Y." Simple messaging often belies more complexity in an issue hiding below the surface. This panel explores that complexity from why bans come about, what's standardized and what's unique to them, and, most importantly, to their highly complex effects: incentivization of illicit markets to satisfy demand; economic impacts from resource diversion for enforcement to losses throughout the value chain; and frustration of overarching THR and wider public health goals tied to consumer demand shifts to illicit products, backsliding to less harm-reduced ones, and social costs of the "illicitization" of products.

Sessions with Eveline Van Keymeulen

Moderators

Dr. Jessica Zdinak

Speakers

Eveline Van Keymeulen